An appellate court's ruling Wednesday against Pfizer Inc. paints the way forward for more racketeering claims against drugmakers who plead guilty to criminal off-label promotion charges as part of a government settlement. Read More
Close to 20,000 attendees from more than 60 countries are expected to converge on Washington for the American Association for Cancer Research's (AACR) annual meeting this weekend and early next week, for science, clinical advances and, the meeting's organizers hope, perhaps even some politics. Read More
Shape Pharmaceuticals Inc. is not aiming to reshape the industry. The Cambridge, Mass.-based biotech has the more modest goal of advancing its single asset, topical histone deacetylase (HDAC) inhibitor SHP-141, in cutaneous T-cell lymphoma (CTCL) and, potentially, other inflammatory skin conditions. Read More
• Trimel Pharmaceuticals Corp., of Toronto, amended its preliminary short form prospectus with details related to changes to a previously announced proposed marketed offering of stock units consisting of one share of common stock and a warrant to purchase one half share. Read More
• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., said it entered a definitive agreement with Summit, N.J.-based Celgene Corp. to sell four Cyclacel-owned patents related to the use of romidepsin injection for a one-time payment of $5.5 million. Read More
• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said one cohort of a Phase II non-small-cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with Tarceva (erlotinib, Astellas Pharma Inc.) to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). Read More
• Noven Pharmaceuticals Inc., of Miami, said it confirmed that it filed an abbreviated new drug application seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage strengths. Read More
